NEWS RELEASE Exhibit 99.1 MATTEL REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Second Quarter 2024 Highlights Versus Prior Year • Net Sales of $1,080 million, down 1% as reported, and comparable in constant currency • Gross Margin of 49.2%, an increase of 410 basis points; Adjusted Gross Margin of 49.2%, an increase of 430 basis points • Operating Income of $83 million, an improvement of $20 million; Adjusted Operating Income of $96 million, an improvement of $21 million • Net Income of $57 million, an impr ...

Toy manufacturer and entertainment specialist Mattel (NASDAQ:MAT) generated business headlines earlier today on reports of a takeover interest. According to Reuters, private equity firm L Catterton — which is backed by luxury goods brand LVMH (OTCMKTS:LVMUY) — offered to buy out the toy company. Mattel stock likely jumped as prior efforts to turn the ship around have not succeeded.Per the report, the news of the asset management firm’s interest in acquiring the entertainment specialist may prompt competing ...

文章核心观点 - 私募股权公司L Catterton(由奢侈品巨头LVMH支持)向玩具制造商美泰公司(Mattel,生产芭比娃娃和Hot Wheels)提出收购要约 [1][2][4] - 这可能会促使其他潜在买家(如竞争对手孩之宝)也考虑对美泰公司进行收购,双方曾多次进行过未果的合并谈判 [2] - 美泰公司正试图通过媒体合作来抵消玩具销售疲软,但其股价在过去12个月内下跌了23% [7] - 美泰公司最近一季度业绩好于预期,得益于成本控制,但仍面临销售疲软的挑战 [8] - 投资者Barington Capital呼吁美泰公司进行改革,包括探索Fisher-Price和American Girl品牌的选择,以及分离CEO和董事长的角色 [9] - 孩之宝也采取了削减成本的措施,最近一季度业绩好于预期 [10][11][12] 公司概况 - 美泰公司是知名玩具制造商,主要产品包括芭比娃娃和Hot Wheels [1][7][9] - 美泰公司总部位于加州埃尔塞贡多,市值约65亿美元 [6][8] - 美泰公司正试图通过媒体合作来抵消玩具销售疲软,但仍面临挑战 [7] - 投资者Barington Capital呼吁美泰公司进行改革 [9] 行业概况 - 私募股权公司L Catterton向美泰公司提出收购要约,可能会引发其他潜在买家的兴趣 [1][2] - 孩之宝也采取了削减成本的措施,最近一季度业绩好于预期 [10][11][12] - 玩具行业面临销售疲软的挑战,企业正采取各种措施应对 [7][8][10][11][12]

~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE39 ...

Mattel aims to make 80% of its games colorblind accessible by the end of the year, before raising that amount to 90% in 2025, the company announced Tuesday.Mattel said the move is part of an inclusivity effort and will target some of its most popular products, including Uno, Phase 10, Dos, Blokus and Tumblin' Monkeys games, according to a press release. The toy manufacturer's portfolio-wide changes will ensure that classic colors are not the only way to differentiate cards or components for the majority of ...

BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at N ...

Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung and bladder cancer patients in H2 2024, including RECIST 1.1 clinical efficacy waterfall, swim-lane plot, ctDNA molecular response analysis, AE profile, PK and pharmacodynamicsInitiating IDE397 Phase 2 monotherapy expansion in MTAP bladder cancer, in addition to the earlier reported Phase 2 expansion in MTAP squamous lung cancerActivated over 35 clinical trial sites globally across the U.S., Canada, Euro ...

BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat with David S. Perlin, PhD, a recognized expert in antifungals. The event is being sponsored by Alliance Global Partners (A.G.P.) ...

Mattel, Inc. (MAT) is likely to benefit from an IP-driven toy business, entertainment offerings and digital initiatives. Also, the emphasis on the Optimizing for Profitable Growth program bodes well. However, an uncertain macroeconomic environment is a concern.Let us discuss the factors that highlight why investors should retain the stock for the time being.Factors Likely to Drive GrowthMattel is actively pursuing its strategy to expand its IP-driven toy business and entertainment offerings to drive growth. ...

Mattel, Inc. (MAT) recently announced a collaboration with Universal Pictures to create a live-action theatrical film, Monster High. The announcement follows MAT’s ongoing success with Hollywood studios in leveraging its intellectual property (IP), as evidenced by Barbie’s stellar performance last year.Based on the popular toy line, the movie follows the teenage offspring of famous monsters like Dracula, Frankenstein and the Wolfman as they navigate the challenges of high school.Launched in 2010, Monster Hi ...